Meeting
2020 Gastrointestinal Cancers Symposium
Pattern of progression in advanced HCC treated with ramucirumab/placebo: Results from two randomized phase III trials (REACH/REACH-2).
Authors
Maria Reig
Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clínic of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain
Maria Reig , Peter R. Galle , Masatoshi Kudo , Richard S. Finn , Josep M. Llovet , William R. Schelman , Kun Liang , Chunxiao Wang , Ryan C. Widau , Paolo Abada , Andrew X. Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01140347 and NCT02435433
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 544)
Abstract #
544
Poster Bd #
D5
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).
First Author: Masatoshi Kudo
Poster
2019 ASCO Annual Meeting
Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).
First Author: Josep M Llovet
Poster
2018 Gastrointestinal Cancers Symposium
A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).
First Author: Andrew X. Zhu
Poster
2015 Gastrointestinal Cancers Symposium
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study.
First Author: Andrew X. Zhu